{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T01:57:25Z","timestamp":1773712645718,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101137141"],"award-info":[{"award-number":["101137141"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101137141"],"award-info":[{"award-number":["101137141"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101137141"],"award-info":[{"award-number":["101137141"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Rare diseases affect over 300 million people worldwide and pose unique research challenges. In silico approaches, such as mechanistic models, machine learning, and simulations, offer scalable tools for disease characterisation, drug discovery, and virtual trials. This review categorises these methods by context of use, critically appraises their strengths and limitations, and identifies barriers to translation, highlighting key opportunities and ongoing challenges in advancing computational strategies for rare disease research.<\/jats:p>","DOI":"10.1038\/s41746-025-02068-1","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:55:53Z","timestamp":1763416553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advancing the frontier of rare disease modeling: a critical appraisal of in silico technologies"],"prefix":"10.1038","volume":"8","author":[{"given":"Francesca","family":"Pistollato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabia","family":"Furtmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay J.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surat","family":"Parvatam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora Tshinanu","family":"Musuamba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Pappalardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"2068_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","volume":"28","author":"S Nguengang Wakap","year":"2020","unstructured":"Nguengang Wakap, S. et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur. J. Hum. Genet. 28, 165\u2013173 (2020).","journal-title":"Eur. J. Hum. Genet."},{"key":"2068_CR2","doi-asserted-by":"crossref","unstructured":"Chan, C. H., Parker, S. & Pearce, D. A. The international rare disease research consortium (IRDiRC): making rare disease research efforts more efficient and collaborative around the world. Rare Dis. Orphan Drugs J. 2, 28 (2023).","DOI":"10.20517\/rdodj.2023.23"},{"key":"2068_CR3","doi-asserted-by":"publisher","first-page":"15821","DOI":"10.3390\/ijms242115821","volume":"24","author":"S Lange","year":"2023","unstructured":"Lange, S. & Inal, J. M. Animal models of human disease. Int. J. Mol. Sci. 24, 15821 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2068_CR4","doi-asserted-by":"crossref","unstructured":"Parvatam, S. et al. Human-based complex in vitro models: their promise and potential for rare disease therapeutics. Front. Cell Dev. Biol. 13, (2025).","DOI":"10.3389\/fcell.2025.1526306"},{"key":"2068_CR5","unstructured":"Unleashing the power of computational tools in rare disease | Clarivate. https:\/\/clarivate.com\/life-sciences-healthcare\/blog\/unleashing-the-power-of-computational-tools-in-rare-disease\/ (2024)."},{"key":"2068_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01026-w","volume":"14","author":"S Marwaha","year":"2022","unstructured":"Marwaha, S., Knowles, J. W. & Ashley, E. A. A guide for the diagnosis of rare and undiagnosed disease: beyond the exome. Genome Med. 14, 23 (2022).","journal-title":"Genome Med."},{"key":"2068_CR7","unstructured":"How third-generation drug discovery is transforming rare disease treatment development. https:\/\/www.nature.com\/articles\/d43747-021-00164-1."},{"key":"2068_CR8","unstructured":"Ekangaki, A. In Silico Modeling Unveils a New Era in Rare Disease Drug Development. Premier Research https:\/\/premier-research.com\/perspectives\/in-silico-modeling-unveils-a-new-era-in-rare-disease-drug-development\/ (2023)."},{"key":"2068_CR9","doi-asserted-by":"publisher","first-page":"103605","DOI":"10.1016\/j.drudis.2023.103605","volume":"28","author":"P Moingeon","year":"2023","unstructured":"Moingeon, P., Chenel, M., Rousseau, C., Voisin, E. & Guedj, M. Virtual patients, digital twins and causal disease models: paving the ground for in silico clinical trials. Drug Discov. Today 28, 103605 (2023).","journal-title":"Drug Discov. Today"},{"key":"2068_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41746-025-01452-1","volume":"8","author":"X Mao","year":"2025","unstructured":"Mao, X. et al. A phenotype-based AI pipeline outperforms human experts in differentially diagnosing rare diseases using EHRs. NPJ Digit. Med. 8, 68 (2025).","journal-title":"NPJ Digit. Med."},{"key":"2068_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02217-9","volume":"17","author":"SD Frederiksen","year":"2022","unstructured":"Frederiksen, S. D. et al. Rare disorders have many faces: in silico characterization of rare disorder spectrum. Orphanet J. Rare Dis. 17, 76 (2022).","journal-title":"Orphanet J. Rare Dis."},{"key":"2068_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-025-00480-w","volume":"10","author":"SW Kong","year":"2025","unstructured":"Kong, S. W. et al. Discordance between a deep learning model and clinical-grade variant pathogenicity classification in a rare disease cohort. NPJ Genom. Med. 10, 17 (2025).","journal-title":"NPJ Genom. Med."},{"key":"2068_CR13","doi-asserted-by":"publisher","first-page":"1404338","DOI":"10.3389\/fmed.2024.1404338","volume":"11","author":"L Cortial","year":"2024","unstructured":"Cortial, L., Montero, V., Tourlet, S., Del Bano, J. & Blin, O. Artificial intelligence in drug repurposing for rare diseases: a mini-review. Front. Med. 11, 1404338 (2024).","journal-title":"Front. Med."},{"key":"2068_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41540-018-0050-7","volume":"4","author":"RG Govindaraj","year":"2018","unstructured":"Govindaraj, R. G., Naderi, M., Singha, M., Lemoine, J. & Brylinski, M. Large-scale computational drug repositioning to find treatments for rare diseases. Npj Syst. Biol. Appl. 4, 1\u201310 (2018).","journal-title":"Npj Syst. Biol. Appl."},{"key":"2068_CR15","doi-asserted-by":"publisher","first-page":"10329","DOI":"10.3390\/ijms251910329","volume":"25","author":"J Gervas-Arruga","year":"2024","unstructured":"Gervas-Arruga, J. et al. In silico modeling of fabry disease pathophysiology for the identification of early cellular damage biomarker candidates. Int. J. Mol. Sci. 25, 10329 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2068_CR16","doi-asserted-by":"publisher","first-page":"643889","DOI":"10.3389\/fnagi.2021.643889","volume":"13","author":"S Esmail","year":"2021","unstructured":"Esmail, S. & Danter, W. R. NEUBOrg: artificially induced pluripotent stem cell-derived brain organoid to model and study genetics of Alzheimer\u2019s disease progression. Front. Aging Neurosci. 13, 643889 (2021).","journal-title":"Front. Aging Neurosci."},{"key":"2068_CR17","unstructured":"FilamenTech | MUSICO platform. https:\/\/filamentech.com\/musico-platform\/."},{"key":"2068_CR18","doi-asserted-by":"publisher","first-page":"108900","DOI":"10.1016\/j.mbs.2022.108900","volume":"352","author":"B Sung","year":"2022","unstructured":"Sung, B. In silico modeling of endocrine organ-on-a-chip systems. Math. Biosci. 352, 108900 (2022).","journal-title":"Math. Biosci."},{"key":"2068_CR19","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/j.xphs.2023.06.019","volume":"112","author":"JP Bai","year":"2023","unstructured":"Bai, J. P., Wang, J., Zhang, Y., Wang, L. & Jiang, X. Quantitative systems pharmacology for rare disease drug development. J. Pharm. Sci. 112, 2313\u20132320 (2023).","journal-title":"J. Pharm. Sci."},{"key":"2068_CR20","unstructured":"The Path to Acceleration: In Silico Modeling Launches New Wave of Rare Disease Drug Development. https:\/\/premier-research.com\/white-papers\/the-path-to-acceleration-in-silico-modeling-launches-new-wave-of-rare-disease-drug-development\/."},{"key":"2068_CR21","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s43441-021-00302-y","volume":"55","author":"M Jahanshahi","year":"2021","unstructured":"Jahanshahi, M. et al. The use of external controls in FDA regulatory decision making. Ther. Innov. Regul. Sci. 55, 1019\u20131035 (2021).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"2068_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20737-y","volume":"8","author":"A Carlier","year":"2018","unstructured":"Carlier, A., Vasilevich, A., Marechal, M., de Boer, J. & Geris, L. In silico clinical trials for pediatric orphan diseases. Sci. Rep. 8, 2465 (2018).","journal-title":"Sci. Rep."},{"key":"2068_CR23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10928-023-09874-8","volume":"50","author":"G Tiraboschi","year":"2023","unstructured":"Tiraboschi, G. et al. Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset Pompe disease. J. Pharmacokinet. Pharmacodyn. 50, 461\u2013474 (2023).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"2068_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10928-024-09912-z","volume":"51","author":"T Li","year":"2024","unstructured":"Li, T. et al. Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions. J. Pharmacokinet. Pharmacodyn. 51, 367\u2013384 (2024).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"2068_CR25","doi-asserted-by":"publisher","first-page":"107541","DOI":"10.1016\/j.pharmthera.2020.107541","volume":"211","author":"LFM Verscheijden","year":"2020","unstructured":"Verscheijden, L. F. M., Koenderink, J. B., Johnson, T. N., de Wildt, S. N. & Russel, F. G. M. Physiologically-based pharmacokinetic models for children: starting to reach maturation?. Pharmacol. Ther. 211, 107541 (2020).","journal-title":"Pharmacol. Ther."},{"key":"2068_CR26","unstructured":"Sehta, S. Difference between PBPK & Population PK Modeling. Allucent https:\/\/www.allucent.com\/resources\/blog\/what-difference-between-pbpk-and-poppk-modeling (2018)."},{"key":"2068_CR27","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1002\/jcph.2143","volume":"62","author":"R-J Li","year":"2022","unstructured":"Li, R.-J. et al. Model-informed approach supporting drug development and regulatory evaluation for rare diseases. J. Clin. Pharmacol. 62, S27\u2013S37 (2022).","journal-title":"J. Clin. Pharmacol."},{"key":"2068_CR28","first-page":"139","volume":"15","author":"H Mozafari","year":"2021","unstructured":"Mozafari, H. et al. Analysis of glucocerebrosidase (GBA) gene mutations in Iranian patients with Gaucher disease. Iran. J. Child Neurol. 15, 139\u2013166 (2021).","journal-title":"J. Child Neurol."},{"key":"2068_CR29","doi-asserted-by":"publisher","unstructured":"Chai, Z. et al. In silico biophysics and rheology of blood and red blood cells in Gaucher Disease. https:\/\/doi.org\/10.1101\/2024.12.10.627687 (2024).","DOI":"10.1101\/2024.12.10.627687"},{"key":"2068_CR30","doi-asserted-by":"publisher","first-page":"130730","DOI":"10.1016\/j.bbagen.2024.130730","volume":"1869","author":"X Xu","year":"2025","unstructured":"Xu, X. et al. 3D structural insights into the effect of N-glycosylation in human chitotriosidase variant G102S. Biochim. Biophys. Acta Gen. Subj. 1869, 130730 (2025).","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"2068_CR31","doi-asserted-by":"publisher","first-page":"8586","DOI":"10.3390\/ijms25168586","volume":"25","author":"JJ Cebolla","year":"2024","unstructured":"Cebolla, J. J., Giraldo, P., G\u00f3mez, J., Montoto, C. & Gervas-Arruga, J. Machine learning-driven biomarker discovery for skeletal complications in type 1 Gaucher disease patients. Int. J. Mol. Sci. 25, 8586 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2068_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12887-020-02481-3","volume":"21","author":"T Tim-Aroon","year":"2021","unstructured":"Tim-Aroon, T. et al. Infantile onset Sandhoff disease: clinical manifestation and a novel common mutation in Thai patients. BMC Pediatr. 21, 22 (2021).","journal-title":"BMC Pediatr."},{"key":"2068_CR33","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1007\/s11011-021-00669-9","volume":"37","author":"Z Rahmani","year":"2022","unstructured":"Rahmani, Z., Banisadr, A., Ghodsinezhad, V., Dibaj, M. & Aryani, O. P. Ala278Val mutation might cause a pathogenic defect in HEXB folding leading to the Sandhoff disease. Metab. Brain Dis. 37, 2669\u20132675 (2022).","journal-title":"Metab. Brain Dis."},{"key":"2068_CR34","first-page":"100495","volume":"20","author":"L Ou","year":"2019","unstructured":"Ou, L., Kim, S., Whitley, C. B. & Jarnes-Utz, J. R. Genotype-phenotype correlation of gangliosidosis mutations using in silico tools and homology modeling. Mol. Genet. Metab. Rep. 20, 100495 (2019).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"2068_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42404-6","volume":"9","author":"SV-N Pereira","year":"2019","unstructured":"Pereira, S. V.-N., Ribeiro, J. D., Ribeiro, A. F., Bertuzzo, C. S. & Marson, F. A. L. Novel, rare and common pathogenic variants in the CFTR gene screened by high-throughput sequencing technology and predicted by in silico tools. Sci. Rep. 9, 6234 (2019).","journal-title":"Sci. Rep."},{"key":"2068_CR36","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/hmg\/ddae028","volume":"33","author":"DC Brock","year":"2024","unstructured":"Brock, D. C. et al. Comparative analysis of in-silico tools in identifying pathogenic variants in dominant inherited retinal diseases. Hum. Mol. Genet. 33, 945\u2013957 (2024).","journal-title":"Hum. Mol. Genet."},{"key":"2068_CR37","doi-asserted-by":"publisher","first-page":"1234032","DOI":"10.3389\/fgene.2023.1234032","volume":"14","author":"M Rodr\u00edguez-Hidalgo","year":"2023","unstructured":"Rodr\u00edguez-Hidalgo, M. et al. ABCA4 c.6480-35A>G, a novel branchpoint variant associated with Stargardt disease. Front. Genet 14, 1234032 (2023).","journal-title":"Front. Genet"},{"key":"2068_CR38","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1016\/j.febslet.2015.11.022","volume":"589","author":"L Paladin","year":"2015","unstructured":"Paladin, L., Tosatto, S. C. E. & Minervini, G. Structural in silico dissection of the collagen V interactome to identify genotype-phenotype correlations in classic Ehlers-Danlos Syndrome (EDS). FEBS Lett. 589, 3871\u20133878 (2015).","journal-title":"FEBS Lett."},{"key":"2068_CR39","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.3390\/ijms25063374","volume":"25","author":"M Calabr\u00f2","year":"2024","unstructured":"Calabr\u00f2, M., Lui, M., Mazzon, E. & D\u2019Angiolini, S. In silico analysis highlights potential predictive indicators associated with secondary progressive multiple sclerosis. Int. J. Mol. Sci. 25, 3374 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2068_CR40","doi-asserted-by":"publisher","first-page":"7551","DOI":"10.3390\/ijms25147551","volume":"25","author":"Y Ma","year":"2024","unstructured":"Ma, Y. et al. Identifying diagnostic markers and constructing predictive models for oxidative stress in multiple sclerosis. Int. J. Mol. Sci. 25, 7551 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2068_CR41","unstructured":"PandaOmics. https:\/\/pharma.ai\/pandaomics."},{"key":"2068_CR42","doi-asserted-by":"publisher","first-page":"914017","DOI":"10.3389\/fnagi.2022.914017","volume":"14","author":"FW Pun","year":"2022","unstructured":"Pun, F. W. et al. Identification of therapeutic targets for amyotrophic lateral sclerosis using Pandaomics - an AI-enabled biological target discovery platform. Front. Aging Neurosci. 14, 914017 (2022).","journal-title":"Front. Aging Neurosci."},{"key":"2068_CR43","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.1007\/s12035-023-03868-w","volume":"61","author":"AM Elasbali","year":"2024","unstructured":"Elasbali, A. M. et al. Discovering promising biomarkers and therapeutic targets for Duchenne muscular dystrophy: a multiomics meta-analysis approach. Mol. Neurobiol. 61, 5117\u20135128 (2024).","journal-title":"Mol. Neurobiol."},{"key":"2068_CR44","doi-asserted-by":"publisher","unstructured":"Russo, G. & Zhang, G. Computational modeling approach to suggest possible therapeutic interventions in spinal muscular atrophy. In 2018 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) 1431\u20131434 https:\/\/doi.org\/10.1109\/BIBM.2018.8621100 (2018).","DOI":"10.1109\/BIBM.2018.8621100"},{"key":"2068_CR45","doi-asserted-by":"publisher","first-page":"133663","DOI":"10.1016\/j.ijbiomac.2024.133663","volume":"275","author":"E Polverini","year":"2024","unstructured":"Polverini, E., Squeri, P. & Gherardi, V. Effect of E134K pathogenic mutation of SMN protein on SMN-SmD1 interaction, with implication in spinal muscular atrophy: a molecular dynamics study. Int. J. Biol. Macromol. 275, 133663 (2024).","journal-title":"Int. J. Biol. Macromol."},{"key":"2068_CR46","doi-asserted-by":"publisher","first-page":"134444","DOI":"10.1016\/j.ijbiomac.2024.134444","volume":"278","author":"R Jenni","year":"2024","unstructured":"Jenni, R. et al. Clinical and genetic spectrum of Ataxia Telangiectasia Tunisian patients: Bioinformatic analysis unveil mechanisms of ATM variants pathogenicity. Int. J. Biol. Macromol. 278, 134444 (2024).","journal-title":"Int. J. Biol. Macromol."},{"key":"2068_CR47","doi-asserted-by":"publisher","first-page":"6378","DOI":"10.1523\/JNEUROSCI.0774-19.2019","volume":"39","author":"X Song","year":"2019","unstructured":"Song, X., Ma, F. & Herrup, K. Accumulation of cytoplasmic DNA due to ATM deficiency activates the microglial viral response system with neurotoxic consequences. J. Neurosci. 39, 6378\u20136394 (2019).","journal-title":"J. Neurosci."},{"key":"2068_CR48","doi-asserted-by":"publisher","first-page":"e0000890","DOI":"10.1371\/journal.pgph.0000890","volume":"2","author":"M Chakraborty","year":"2022","unstructured":"Chakraborty, M. et al. Rare disease patients in India are rarely involved in international orphan drug trials. PLOS Glob. public health 2, e0000890 (2022).","journal-title":"PLOS Glob. public health"}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02068-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02068-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02068-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:55:56Z","timestamp":1763416556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02068-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2068"],"URL":"https:\/\/doi.org\/10.1038\/s41746-025-02068-1","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"24 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"676"}}